SUMMARY - Comparison with HUMIRA and KEYTRUDA
Post# of 148190
(Total Views: 1318)
Posted On: 10/10/2019 9:38:33 AM
SUMMARY
- Comparison with HUMIRA and KEYTRUDA
- Clinical portion of BLA submitted by November; manufacturing portion in December unless FDA allows them to submit stability data during review process
- MOA in cancer: Bruce Patterson, stopping macrophages, allowing T-cells to kill the tumour
- Licensing talks: costs of launch on partner, 90m milestones payment, 50% of royalties minus standard costs and costs of goods plus 10% (??), hoping to complete the deal "very, very soon".
- Going to raise 10 or 15m to get to end of the year; Dr. Sacha in contact with US army for PrEP; Thai red cross; GvHD first injection this month.
- Very very happy, very excited to get licensing agreement done and perhaps sell one or to non-HIV indications, to get human data in TNBC; potential in any of the indications is huge.
- Comparison with HUMIRA and KEYTRUDA
- Clinical portion of BLA submitted by November; manufacturing portion in December unless FDA allows them to submit stability data during review process
- MOA in cancer: Bruce Patterson, stopping macrophages, allowing T-cells to kill the tumour
- Licensing talks: costs of launch on partner, 90m milestones payment, 50% of royalties minus standard costs and costs of goods plus 10% (??), hoping to complete the deal "very, very soon".
- Going to raise 10 or 15m to get to end of the year; Dr. Sacha in contact with US army for PrEP; Thai red cross; GvHD first injection this month.
- Very very happy, very excited to get licensing agreement done and perhaps sell one or to non-HIV indications, to get human data in TNBC; potential in any of the indications is huge.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼